Loading stock data…
$13.48+0.06 (+0.45%)
Jade Biosciences, Inc.
Jade Biosciences, Inc. in the Healthcare sector is trading at $13.48 with a market capitalization of $915M. Wall Street consensus targets $50.12 (8 analysts), implying a +271.8% move over the next 12 months. The stock is currently 52% below its 52-week high of $28.00, remaining 26.1% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$58.92M↓ | -$43.45M↓ | -$34.98M↓ | -$27.40M↑ | -$27.78M |
| Net Income | -$55.77M↓ | -$40.37M↓ | -$31.93M↓ | -$25.18M↑ | -$32.13M |
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Induci...